Effects of Dietary Fish Oil on Serum Lipids and Blood Coagulation in Peritoneal Dialysis Patients

The effects of a daily fish oil supplement rich in eicosapentaenoic acid were studied in 11 stable continuous ambulatory peritoneal dialysis (CAPD) patients. Serum lipids, platelet aggregation studies, and template bleeding times were determined before and after 4 weeks of fish oil treatment. The lipid studies were repeated approximately 20 weeks after stopping fish oil supplement. At the end of the treatment period, serum triglycerides (mean ± SEM) decreased from 297 ± 42 to 211 ± 29 mg/dL (P < .01), high density lipoprotein (HDL) cholesterol fell from 45 ± 3 to 41 ± 3 mg/dL (P < .05), and low density lipoprotein (LDL) cholesterol increased from 172 ± 16 to 208 ± 19 mg/dL (P < .05). After discontinuing the fish oil supplement, the triglycerides increased to 278 ± 39 mg/dL, which was no different than the value before fish oil treatment. No significant changes occurred in template bleeding time (TBT), platelet count, hematocrit, or platelet aggregation response. Clinically important uremic bleeding was not apparent. We conclude that in CAPD patients a fish oil supplement favorably effects hypertriglyceridemia and can be ingested without promoting uremic bleeding. The likely beneficial impact on atherogenesis resulting from the lowering of the triglycerides may, however, be counteracted by concomitant changes in HDL- and LDL-cholesterol.